Earnings release
Page 1
Exhibit 99.1 Protolabs Reports Financial Results for the Third Quarter of 2026 Record Quarterly Revenue of $154.3 Million, a 14.0% Increase Year-Over-Year GAAP Earnings Per Share of $0.48, up 61% YoY; Non-GAAP Earnings Per Share of $0.63, up 33% YoY Raising Full Year 2026 Revenue Growth Guidance from 8% - 10% to 10% - 11% MINNEAPOLIS – October 29, 2026 – Proto Labs, Inc. ("Protolabs" or the "Company") (NYSE: PRLB), the world’s leading provider of digital manufacturing services, today announced financial results for the third quarter ended September 30, 2026. Third Quarter 2026 Financial Highlights: • Revenue was a record $154.3 million, a 14.0% increase over the third quarter of 2025. ◦ Total revenue per customer contact increased 16.6% year-over-year. ◦ CNC machining revenue grew 16.4% year-over-year. ◦ Injection molding revenue grew 12.5% year-over-year. ◦ 3D printing revenue grew 11.4% year-over-year. • GAAP operating margin was 9.4%, up from 6.5% in the third quarter of 2025. Non-GAAP operating margin was 11.9%, up from 10.0% in the third quarter of 2025. • GAAP net income was $0.48 per diluted share, compared to $0.30 per diluted share in the third quarter of 2025. Non-GAAP net income was $0.63 per diluted share, compared to $0.47 per diluted share in the third quarter of 2025. Note: See “Non-GAAP Financial Measures” below. "Protolabs delivered another record quarter, with double-digit revenue growth for the fourth consecutive quarter," said Suresh Krishna, President and Chief Executive Officer. "Our momentum reflects strong execution and growing demand from industries that value speed, quality, and manufacturing agility. As reindustrialization, advanced hardware innovation, and the need for resilient supply chains reshape manufacturing, our digital model enables customers to move quickly from idea to production — positioning us to deliver sustained profitable growth and long-term shareholder value." Additional Third Quarter 2026 Financial Highlights: • GAAP net income was $11.8 million, or 7.6% of revenue, up 63.0% compared to $7.2 million, or 5.3% of revenue in the third quarter of 2025. • Adjusted EBITDA was $26.2 million, or 17.0% of revenue, up 23.8% compared to $21.1 million, or 15.6% of revenue, in the third quarter of 2025. See “Non-GAAP Financial Measures” below. • Cash generated from operations was $22.8 million. • Cash and investments balance was $175.0 million as of September 30, 2026. "We delivered another quarter of strong financial performance, with broad-based revenue growth, meaningful operating leverage, and continued earnings growth," said Dan Schumacher, Chief Financial Officer. "We remain focused on balancing investments in our strategic priorities with disciplined cost management, while generating strong cash flow and positioning the business for sustained profitable growth." Financial Guidance and Outlook: • For full year 2026, Protolabs is raising its guidance and now expects revenue growth between 10% and 11%. • For the fourth quarter of 2026, the Company expects revenue between $143.0 million and $151.0 million.
Page 2
• For the fourth quarter of 2026, the Company expects GAAP diluted net income per share between $0.28 and $0.36, and non- GAAP diluted net income per share between $0.46 and $0.54. See "Non-GAAP Financial Measures" below. Non-GAAP Financial Measures The Company has included non-GAAP revenue growth by region and by product line that excludes the impact of changes in foreign currency exchange rates (collectively, “non-GAAP revenue growth”). Management believes these metrics, when viewed in conjunction with the comparable metrics calculated in accordance with generally accepted accounting principles in the United States ("GAAP"), are useful in evaluating the underlying business trends and ongoing operating performance of the Company. The Company has included earnings before interest, taxes, depreciation and amortization (“EBITDA”) and EBITDA, adjusted for stock- based compensation expense, unrealized loss (gain) on foreign currency, trade refunds and charges, net, restructuring and transformation costs, costs related to exit and disposal activities and CEO transition costs (collectively, “Adjusted EBITDA”), in this press release to provide investors with additional information regarding the Company’s financial results. The Company has also included earnings before interest, taxes, depreciation and amortization margin (“EBITDA margin”) and EBITDA margin, adjusted for stock-based compensation expense, unrealized loss (gain) on foreign currency, trade refunds and charges, net, restructuring and transformation costs, costs related to exit and disposal activities and CEO transition costs (“Adjusted EBITDA margin”), in this press release to provide investors with additional information regarding the Company’s financial results. The Company has included non-GAAP gross margin, adjusted for stock-based compensation expense, amortization expense and trade refunds and charges, net ("non-GAAP gross margin"), in this press release to provide investors with additional information regarding the Company’s financial results. The Company has included non-GAAP operating margin, adjusted for stock-based compensation expense, amortization expense, trade refunds and charges, net, restructuring and transformation costs, costs related to exit and disposal activities and CEO transition costs (“non-GAAP operating margin”), in this press release to provide investors with additional information regarding the Company’s financial results. The Company has included non-GAAP net income and non-GAAP net income per share, in each case, adjusted for stock-based compensation expense, amortization expense, unrealized loss (gain) on foreign currency, trade refunds and charges, net, restructuring and transformation costs, costs related to exit and disposal activities and CEO transition costs (“non-GAAP net income” and "non-GAAP net income per share", respectively), in this press release to provide investors with additional information regarding the Company’s financial results. The Company has provided below reconciliations of GAAP to non-GAAP net income, non-GAAP net income per share, non-GAAP gross margin, non-GAAP operating margin, non-GAAP revenue growth by region and by product line, EBITDA, EBITDA margin, Adjusted EBITDA and Adjusted EBITDA margin to the most directly comparable measures calculated and presented in accordance with GAAP. These non- GAAP measures are used by the Company’s management and board of directors to understand and evaluate operating performance and trends, provide useful measures for period-to-period comparisons of the Company’s business, and in determining executive and senior management incentive compensation. Accordingly, the Company believes that these non-GAAP measures provide useful information to investors and others in understanding and evaluating operating results in the same manner as the Company's management and board of directors. These non-GAAP financial measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP. These non-GAAP financial measures exclude significant expenses and income that are required by GAAP to be recorded in the Company's condensed consolidated financial statements and are subject to inherent limitations. Investors should review the reconciliations of non-GAAP financial measures to the comparable GAAP financial measures that are included in this press release. Conference Call The Company has scheduled a conference call to discuss its third quarter 2026 financial results and fourth quarter 2026 outlook today, October 29, 2026, at 8:30 a.m. EDT. To access the call in the U.S., please dial 877-709-8150 or outside the U.S. dial 201-689-8354 at least five minutes prior to the 8:30 a.m. EDT start time. No participant code is required. A simultaneous webcast of the call and accompanying presentation will be available via the investor relations section of the Protolabs website and the following link: https://edge.media- server.com/mmc/p/ec8fzrj2/. A replay will be available for 14 days following the call on the investor relations section of the Protolabs website.
Page 3
About Protolabs Protolabs is the world’s fastest manufacturing service enabling companies across every industry to streamline production of quality parts throughout the entire product life cycle. From custom prototyping to end-use production, we support product developers, engineers, and supply chain teams along every phase of their manufacturing journey. Get started now at protolabs.com. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical or current facts are “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties and other factors which may cause the results of Protolabs to be materially different than those expressed or implied in such statements. Certain of these risk factors and others are described in the “Risk Factors” section within reports filed with the SEC. Other unknown or unpredictable factors also could have material adverse effects on Protolabs’ future results. The forward-looking statements included in this press release are made only as of the date hereof. Protolabs cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, Protolabs expressly disclaims any intent or obligation to update any forward-looking statements to reflect subsequent events or circumstances. Source: Proto Labs, Inc. Investor Relations Contacts Protolabs Ryan Johnsrud, 612-225-4873 Sr. Manager – Investor Relations and Corporate Development ryan.johnsrud@protolabs.com Gateway Group, Inc. 949-574-3860 PRLB@gateway-grp.com Media Contact Protolabs Brent Renneke, 763-479-7704 Corporate Communications Manager brent.renneke@protolabs.com
Page 4
Proto Labs, Inc. Condensed Consolidated Balance Sheets (In thousands) September 30,2026 December 31,2025 (Unaudited) Assets Current assets Cash and cash equivalents $ 133,780 $ 110,826 Short-term marketable securities 17,366 17,297 Accounts receivable, net 99,256 78,962 Inventory 16,538 14,401 Prepaid expenses and other current assets 11,844 9,590 Income taxes receivable 744 2,465 Total current assets 279,528 233,541 Property and equipment, net 206,932 215,261 Goodwill 273,991 273,991 Other intangible assets, net 15,663 18,612 Long-term marketable securities 23,903 14,308 Operating lease assets 3,130 2,836 Finance lease assets — 424 Other long-term assets 4,874 4,442 Total assets $ 808,021 $ 763,415 Liabilities and shareholders' equity Current liabilities Accounts payable $ 18,991 $ 15,104 Accrued compensation 24,632 23,674 Accrued liabilities and other 31,755 26,783 Current operating lease liabilities 1,239 1,155 Current finance lease liabilities — 286 Total current liabilities 76,617 67,002 Long-term operating lease liabilities 2,664 1,606 Long-term deferred tax liabilities 22,269 16,598 Other long-term liabilities 4,667 4,277 Shareholders' equity 701,804 673,932 Total liabilities and shareholders' equity $ 808,021 $ 763,415
Page 5
Proto Labs, Inc. Condensed Consolidated Statements of Operations (In thousands, except share and per share amounts) (Unaudited) Three Months EndedSeptember 30, Nine Months EndedSeptember 30, 2026 2025 2026 2025 Revenue Injection Molding $ 53,730 $ 47,770 $ 158,423 $ 143,908 CNC Machining 73,359 63,043 206,964 177,831 3D Printing 22,364 20,082 63,496 61,491 Sheet Metal 4,063 4,262 12,876 12,776 Other Revenue 802 209 1,236 628 Total revenue 154,318 135,366 442,995 396,634 Cost of revenue 85,655 74,073 241,398 219,869 Gross profit 68,663 61,293 201,597 176,765 Operating expenses Marketing and sales 24,528 24,574 74,990 73,054 Research and development 11,019 10,705 32,350 32,487 General and administrative 18,241 17,163 54,903 52,763 Restructuring and transformation costs 434 — 2,779 — Costs related to exit and disposal activities — 41 937 151 Total operating expenses 54,222 52,483 165,959 158,455 Income from operations 14,441 8,810 35,638 18,310 Other income, net 1,766 1,441 4,489 4,600 Income before income taxes 16,207 10,251 40,127 22,910 Provision for income taxes 4,445 3,035 11,102 7,668 Net income $ 11,762 $ 7,216 $ 29,025 $ 15,242 Net income per share: Basic $ 0.49 $ 0.30 $ 1.21 $ 0.64 Diluted $ 0.48 $ 0.30 $ 1.19 $ 0.63 Shares used to compute net income per share: Basic 24,024,031 23,889,157 23,943,656 23,974,054 Diluted 24,438,800 24,191,039 24,398,409 24,249,669
Page 6
Proto Labs, Inc. Condensed Consolidated Statements of Cash Flows (In thousands) (Unaudited) Nine Months EndedSeptember 30, 2026 2025 Operating activities Net income $ 29,025 $ 15,242 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 24,269 25,693 Stock-based compensation expense 10,658 11,928 Deferred taxes 5,563 2,355 Interest on finance lease obligations 5 16 Loss on impairment of equipment 186 — Impairments related to exit and closure of facilities 937 448 Gain on disposal of property and equipment (150) 16 Other (172) (179) Changes in operating assets and liabilities (14,575) 2,355 Net cash provided by operating activities 55,746 57,874 Investing activities Purchases of property, equipment and other capital assets (15,539) (6,792) Proceeds from sales of property, equipment and other capital assets 1,279 811 Purchases of marketable securities (25,507) (13,553) Proceeds from maturities of marketable securities 15,475 11,730 Net cash used in investing activities (24,292) (7,804) Financing activities Proceeds from issuance of common stock from equity plans 8,011 4,195 Purchases of shares withheld for tax obligations (6,083) (3,119) Repurchases of common stock (10,038) (36,732) Principal repayments of finance lease obligations (187) (231) Net cash used in financing activities (8,297) (35,887) Effect of exchange rate changes on cash and cash equivalents (203) 989 Net increase in cash and cash equivalents 22,954 15,172 Cash and cash equivalents, beginning of period 110,826 89,071 Cash and cash equivalents, end of period $ 133,780 $ 104,243
Page 7
Proto Labs, Inc. Reconciliation of GAAP to Non-GAAP Net Income and Non-GAAP Net Income per Share (In thousands, except share and per share amounts) (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2026 2025 2026 2025 Non-GAAP net income, adjusted for stock-basedcompensation expense, amortization expense,unrealized loss (gain) on foreign currency, traderefunds and charges, net, restructuring andtransformation costs, costs related to exit and disposalactivities and CEO transition costs GAAP net income $ 11,762 $ 7,216 $ 29,025 $ 15,242 Add back: Stock-based compensation expense 3,351 3,677 10,658 11,928 Amortization expense 902 935 2,720 2,770 Unrealized loss (gain) on foreign currency 129 (2) 266 (316) Trade refunds and charges, net (709) — (1,036) — Restructuring and transformation costs 434 — 2,779 — Costs related to exit and disposal activities — 41 937 151 CEO transition costs — 14 — 1,376 Total adjustments 4,107 4,665 16,324 15,909 Income tax benefits on adjustments (531) (500) (2,228) (1,700) Non-GAAP net income $ 15,338 $ 11,381 $ 43,121 $ 29,451 Non-GAAP net income per share: Basic $ 0.64 $ 0.48 $ 1.80 $ 1.23 Diluted $ 0.63 $ 0.47 $ 1.77 $ 1.21 Shares used to compute non-GAAP net income pershare: Basic 24,024,031 23,889,157 23,943,656 23,974,054 Diluted 24,438,800 24,191,039 24,398,409 24,249,669 Stock-based compensation expense, amortization expense, unrealized loss (gain) on foreign currency, trade refunds and charges, net, restructuring and transformation costs, costs related to exit and disposal activities and CEO transition costs were included in the following GAAP consolidated statement of operations categories: 1 2 1
Page 8
Three Months EndedSeptember 30, Nine Months EndedSeptember 30, 2026 2025 2026 2025 Cost of revenue $ 85 $ 781 $ 1,370 $ 2,350 Marketing and sales 798 837 2,322 2,423 Research and development 629 764 1,698 2,124 General and administrative 2,032 2,244 6,952 9,177 Restructuring and transformation costs 434 — 2,779 — Costs related to exit and disposal activities — 41 937 151 Total operating expenses 3,893 3,886 14,688 13,875 Other income, net 129 (2) 266 (316) Total adjustments $ 4,107 $ 4,665 $ 16,324 $ 15,909 2 For the three and nine months ended September 30, 2026 and 2025, income tax effects were calculated using the effective tax rate for the relevant jurisdictions. The Company's non-GAAP tax rates differ from its GAAP tax rates due primarily to the mix of activity incurred in domestic and foreign tax jurisdictions and removing effective tax rate benefits from stock-based compensation activity in the respective period.
Page 9
Proto Labs, Inc. Reconciliation of GAAP to Non-GAAP Gross Margin (In thousands) (Unaudited) Three Months EndedSeptember 30, Nine Months EndedSeptember 30, 2026 2025 2026 2025 Revenue $ 154,318 $ 135,366 $ 442,995 $ 396,634 Gross profit 68,663 61,293 201,597 176,765 GAAP gross margin 44.5% 45.3% 45.5% 44.6% Add back: Stock-based compensation expense 451 439 1,379 1,323 Amortization expense 343 342 1,027 1,027 Trade refunds and charges, net (709) — (1,036) — Total adjustments 85 781 1,370 2,350 Non-GAAP gross profit $ 68,748 $ 62,074 $ 202,967 $ 179,115 Non-GAAP gross margin 44.5% 45.9% 45.8% 45.2%
Page 10
Proto Labs, Inc. Reconciliation of GAAP to Non-GAAP Operating Margin (In thousands) (Unaudited) Three Months EndedSeptember 30, Nine Months EndedSeptember 30, 2026 2025 2026 2025 Revenue $ 154,318 $ 135,366 $ 442,995 $ 396,634 Income from operations 14,441 8,810 35,638 18,310 GAAP operating margin 9.4% 6.5% 8.0% 4.6% Add back: Stock-based compensation expense 3,351 3,677 10,658 11,928 Amortization expense 902 935 2,720 2,770 Trade refunds and charges, net (709) — (1,036) — Restructuring and transformation costs 434 — 2,779 — Costs related to exit and disposal activities — 41 937 151 CEO transition costs — 14 — 1,376 Total adjustments 3,978 4,667 16,058 16,225 Non-GAAP income from operations $ 18,419 $ 13,477 $ 51,696 $ 34,535 Non-GAAP operating margin 11.9% 10.0% 11.7% 8.7%
Page 11
Proto Labs, Inc. Reconciliation of GAAP Net Income to EBITDA and Adjusted EBITDA (In thousands) (Unaudited) Three Months EndedSeptember 30, Nine Months EndedSeptember 30, 2026 2025 2026 2025 Revenue $ 154,318 $ 135,366 $ 442,995 $ 396,634 GAAP net income 11,762 7,216 29,025 15,242 GAAP net income margin 7.6% 5.3% 6.6% 3.8% Add back: Amortization expense $ 902 $ 935 $ 2,720 $ 2,770 Depreciation expense 7,206 7,494 21,549 22,923 Interest income, net (1,355) (1,281) (3,939) (3,532) Provision for income taxes 4,445 3,035 11,102 7,668 EBITDA 22,960 17,399 60,457 45,071 EBITDA margin 14.9% 12.9% 13.6% 11.4% Add back: Stock-based compensation expense 3,351 3,677 10,658 11,928 Unrealized loss (gain) on foreign currency 129 (2) 266 (316) Trade refunds and charges, net (709) — (1,036) — Restructuring and transformation costs 434 — 2,779 — Costs related to exit and disposal activities — 41 937 151 CEO transition costs — 14 — 1,376 Total adjustments 3,205 3,730 13,604 13,139 Adjusted EBITDA $ 26,165 $ 21,129 $ 74,061 $ 58,210 Adjusted EBITDA margin 17.0% 15.6% 16.7% 14.7%
Page 12
Proto Labs, Inc. Comparison of GAAP to Non-GAAP Revenue Growth by Region (In thousands) (Unaudited) Three Months Ended September 30, 2026 Three Months Ended September 30, 2025 % Change % Change OrganicGAAP Foreign Currency Non-GAAP GAAP Revenues United States $ 125,412 $ — $ 125,412 $ 109,361 14.7% 14.7% Europe 28,906 267 29,173 26,005 11.2 12.2 Total revenue $ 154,318 $ 267 $ 154,585 $ 135,366 14.0% 14.2% Nine Months Ended September 30, 2026 Nine Months Ended September 30, 2025 % Change % Change OrganicGAAP Foreign Currency Non-GAAP GAAP Revenues United States $ 360,298 $ — $ 360,298 $ 320,340 12.5% 12.5% Europe 82,697 (2,337) 80,360 76,294 8.4 5.3 Total revenue $ 442,995 $ (2,337) $ 440,658 $ 396,634 11.7% 11.1% 1 Revenue for the three and nine months ended September 30, 2026 has been recalculated using 2025 foreign currency exchange rates in effect during comparable periods to provide information useful in evaluating the underlying business trends excluding the impact of changes in foreign currency exchange rates. 2 This column presents the percentage change from GAAP revenue for the three and nine months ended September 30, 2025 to GAAP revenue for the three and nine months ended September 30, 2026. 3 This column presents the percentage change from GAAP revenue for the three and nine months ended September 30, 2025 to non- GAAP revenue for the three and nine months ended September 30, 2026 (as recalculated using the foreign currency exchange rates in effect during the three and nine months ended September 30, 2025) in order to provide a constant-currency comparison. 2 31 2 31
Page 13
Proto Labs, Inc. Comparison of GAAP to Non-GAAP Revenue Growth by Product Line (In thousands) (Unaudited) Three Months Ended September 30, 2026 Three Months EndedSeptember 30, 2025 % Change % Change OrganicGAAP Foreign Currency Non-GAAP GAAP Revenues Injection Molding $ 53,730 $ 46 $ 53,776 $ 47,770 12.5% 12.6% CNC Machining 73,359 184 73,543 63,043 16.4 16.7 3D Printing 22,364 29 22,393 20,082 11.4 11.5 Sheet Metal 4,063 2 4,065 4,262 (4.7) (4.6) Other Revenue 802 6 808 209 283.7 286.6 Total revenue $ 154,318 $ 267 $ 154,585 $ 135,366 14.0% 14.2% Nine Months Ended September 30, 2026 Nine Months EndedSeptember 30, 2025 % Change % Change OrganicGAAP Foreign Currency Non-GAAP GAAP Revenues Injection Molding $ 158,423 $ (674) $ 157,749 $ 143,908 10.1% 9.6% CNC Machining 206,964 (1,248) 205,716 177,831 16.4 15.7 3D Printing 63,496 (369) 63,127 61,491 3.3 2.7 Sheet Metal 12,876 (48) 12,828 12,776 0.8 0.4 Other Revenue 1,236 2 1,238 628 96.8 97.1 Total revenue $ 442,995 $ (2,337) $ 440,658 $ 396,634 11.7% 11.1% 1 Revenue for the three and nine months ended September 30, 2026 has been recalculated using 2025 foreign currency exchange rates in effect during comparable periods to provide information useful in evaluating the underlying business trends excluding the impact of changes in foreign currency exchange rates. 2 This column presents the percentage change from GAAP revenue for the three and nine months ended September 30, 2025 to GAAP revenue for the three and nine months ended September 30, 2026. 3 This column presents the percentage change from GAAP revenue for the three and nine months ended September 30, 2025 to non- GAAP revenue for the three and nine months ended September 30, 2026 (as recalculated using the foreign currency exchange rates in effect during the three and nine months ended September 30, 2025) in order to provide a constant-currency comparison. 2 31 2 31
Page 14
Proto Labs, Inc. Customer Contact Information (In thousands, except customer contacts and per customer contact amounts) (Unaudited) Three Months EndedSeptember 30, Nine Months EndedSeptember 30, 2026 2025 2026 2025 Revenue $ 154,318 $ 135,366 $ 442,995 $ 396,634 Customer contacts 20,777 21,252 40,129 41,873 Revenue per customer contact $ 7,427 $ 6,370 $ 11,039 $ 9,472 1 Revenue per customer contact is calculated using the revenue recognized during the respective period divided by the actual number of customer contacts served during the same period. Customer contacts are product developers, engineers, procurement and supply chain professionals and other individuals who place an order, and that order is shipped and invoiced during the period. The Company believes revenue per customer contact is useful to investors in evaluating the underlying business trends and ongoing operating performance of the Company. Proto Labs, Inc. Reconciliation of GAAP to Non-GAAP Guidance (Unaudited) Q4 2026 Outlook Low High GAAP diluted net income per share $ 0.28 $ 0.36 Add back: Stock-based compensation expense 0.15 0.15 Amortization expense 0.03 0.03 Total adjustments 0.18 0.18 Non-GAAP diluted net income per share $ 0.46 $ 0.54 1